Navidea Biopharmaceuticals Inc (NAVB) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Navidea Biopharmaceuticals Inc   (NAVB)

Navidea Biopharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Navidea Biopharmaceuticals Inc in the third quarter 2023?
Due to the lack of equity, it was not possible to calculate Navidea Biopharmaceuticals Inc 's return on equity (ROE) in its third quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -1 -5 -14 -15 -15
Return On Equity (TTM) - - - - -
NAVB's Total Ranking # # # # #
Equity (TTM) in Millions -3 -1 -10 -8 -5
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to NAVB Management Effectiveness >> NAVB's 5 Years Annual ROE >> Compare NAVB ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





NAVB Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Equity in Millions -8 1 2 -1 2
Y / Y Equity Change - -69.48 % - - -79.99 %
Net Income in Millions -15 -12 -11 -11 -16
Y / Y Net Income Change - - - - -
Return On Equity - -1877.72 % -523.8 % - -668.52 %

Back to NAVB Management Effectiveness >> NAVB's 5 Years Annual ROE >> Compare NAVB ROE to its Competitors




More Return On Equity Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NAVB's' Return on Equity at Yahoo Finance
NAVB's Roe Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NAVB's Competitors
Subscribers only: Roe for Navidea Biopharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for NAVB's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE
Cv Sciences Inc   56.96 %
Elite Pharmaceuticals Inc   55.08 %
Omeros Corporation  54.32 %
Vaso Corporation  50.49 %
Zoetis Inc   49.00 %
Enzo Biochem Inc  47.55 %
Star Equity Holdings Inc   47.18 %
Abbvie Inc   46.90 %
Johnson and Johnson  46.90 %
Eli Lilly And Company  44.81 %
Zymeworks Inc   44.62 %
Escalon Medical Corp   42.84 %
Entera Bio Ltd   42.52 %
Tenet Healthcare Corp  42.44 %
Shockwave Medical Inc   42.41 %
Nrc Health  40.74 %
Baxter International Inc   40.60 %
Viskase Holdings inc   35.29 %
Tao Synergies Inc   34.96 %
Arcturus Therapeutics Holdings Inc   34.11 %
Harmony Biosciences Holdings inc   33.27 %
Macrogenics Inc   32.31 %
Voyager Therapeutics Inc   32.13 %
Semler Scientific inc   30.96 %
Denali Therapeutics Inc   30.61 %
Agilent Technologies inc   30.40 %
Gilead Sciences Inc   27.28 %
Exicure Inc   27.15 %
Bruker Corporation  26.84 %
Chemed Corporation  26.80 %

Date modified: 2026-08-29T17:28:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.